Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients

American Journal of Transplantation

Volumn 4, Issue 11, 2004, Pages 1810-1817

  Formea, Christine M ^a   Myers Huentelman, Heather ^a   Wu, Rongling ^b   Crabtree, Janet ^c   Fujita, Shiro ^c   Hemming, Alan ^c   Reed, Alan ^c   Howard, Richard ^c   Karlix, Janet L ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Azathioprine; Genomics; Immunosuppression; Pharmacogenetics; Thiopurine S methyltransferase; TPMT

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

ADULT; AFRICAN AMERICAN; ALLELE; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CAUCASIAN; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ASSAY; ETHNIC DIFFERENCE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; GRAFT REJECTION; HEMATOCRIT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; REACTION OPTIMIZATION; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADULT; AZATHIOPRINE; BLOOD CELL COUNT; CREATININE; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METHYLTRANSFERASES; MIDDLE AGED; MYCOPHENOLIC ACID; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SPINAL CORD; VARIATION (GENETICS);

EID: 7244261983     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00575.x     Document Type: Article

References (45)

1. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53: 1051.
2. Thervet E, Anglicheau D, Toledano N et al. Long-term results of TPMT activity monitoring in azathioprine-treated renal allograft recipients. J Am Soc Nephrol 2001; 12: 170.
3. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3 (Suppl 1): S30.
4. Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716.
5. Langley PG, Underhill J, Tredger M, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002; 37: 441.
6. Estlin EJ. Continuing therapy for childhood acute lymphoblastic leukaemia: Clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Cancer Treat Rev 2001; 27: 351.
7. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 567.
8. 2002 Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1991-2001. Rockville, MD and Richmond, VA: HHS/HRSA/OSP/DOTand UNOS.
9. Yates CF, Krynetski EY, Loennenchen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608.
10. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppession in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341: 436.
11. Pandya B, Thomson W, Poulton K, Bruce I, Payne D, Qasim F. Azathioprine toxicity and thiopurine methyltransferase genotype in renal transplant patients. Transpl Proc 2002; 34: 1642.
12. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001.
13. Remy CN. Metabolism of thiopyrimidines and thiopurines. J Biol Chem 1963; 238: 1078.
14. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651.
15. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphisms of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371.
16. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225.
17. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994; 343: 1188.
18. Koren G, Ferrazini G, Sulh H et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 1990; 323: 17.
19. Dubinsky MC, Lamothe S, Yang HY. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705.
20. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642.
21. Evans WE, Johnson JA. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9.
22. Evans WE, McLeod HL. Pharmacogenomics-Drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538.
23. National Kidney Foundation. National kidney foundation /Dialysis Outcomes Quality Initiative (NKF/DOQI) clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001; 37 (Suppl 1): S182.
24. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-Implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89.
25. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm. Pharm Res 1999; 16: 342.
26. Al-Uzri A, Yorgin PD, Kling PJ. Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 2003; 7: 253.
27. Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002; 40: 1306.
28. Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients. Am J Transplant 2003; 3: 835.
29. EBPG expert group on renal transplantation. European best practice guidelines for renal transplantation. Section IV; Long-term management of the transplant recipient. IV.9.1. Haematological complications. Anaemia. Nephrol Dial Transplant 2002; 17 (Suppl 4): 48.
30. Sebbag L, Boucher P, Davelu P et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 2000; 69: 1524.
31. Mann JFE. What are the short-term and long-term consequences of anemia in CRF patients? Nephrol Dial Transplant 1999; 14 (Suppl 2): 29.
32. Yorgin PD, Scandling JD, Belson A et al. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2002; 2: 429.
33. Kessler M. Erythropoietin and erythropoiesis in renal transplantation. Nephrol Dial Transplant 1995; 10 (Suppl 6): 114.
34. Lezaic V, Djukanovic LJ, Pavlovic-Kentera V, demons G, Biljanovic-Paunovic L. Factors inducing posttransplant erythrocytosis. Eur J Med Res 1997; 2: 407.
35. Perry SS, Kim MJ, Spangrude GJ. Direct effects of cyclosporin A on proliferation of hematopoietic stem and progenitor cells. Cell Transplant 1999; 8: 339.
36. Clarke E, Quinn DG, McCann SR. Inhibitory effect of cyclosporin A on erythroid and stromal colonies. Eur J Haematol 1991; 47: 282.
37. Jensen JD, Hansen HE, Pedersen ER. Increased serum erythropoietin level during azathioprine treatment in renal transplant recipients. Nephron 1994; 67: 297.
38. Vannucchi AM, Grossi A, Bosi A, et al. Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood 1993; 82: 978.
39. Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation 2000; 69 (Suppl 12): SS5.
40. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 2000; 69 (Suppl 12): SS11.
41. Weyer N, Kroplin T, Fricke L, Iven H. Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol 2001; 57: 129.
42. Colombel JF, Ferrrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025.
43. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996; 18: 228.
44. Prometheus Laboratories. Package literature for Imuran®. Available at http://www.prometheuslabs.com/pi/lmuran.pdf, accessed on April 2004.
45. Lesko LJ. Pharmacogenetics: Improvement of existing drug treatments. Presentation to FDA's Clinical Pharmacology Subcommittee Advisory Committee for Pharmaceutical Sciences. Rockville, MD. April 22-23, 2003. Available at http://www.fda.gov/ohrms/dockets/ac/03/slides/3947s2.htm, accessed on May 1, 2004.